Kubo, A., Nakagawa, K., Varma, R. K., Conrad, N. K., Cheng, J. Q., Lee, W. C., … Kelley, M. J. (1999). The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin dependent kinase (CDK) 4. CLINICAL CANCER RESEARCH, 5, 3755S-3756S.

Kubo, A., K. Nakagawa, R. K. Varma, N. K. Conrad, J. Q. Cheng, W. C. Lee, J. R. Testa, B. E. Johnson, F. J. Kaye, and M. J. Kelley. “The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin dependent kinase (CDK) 4.” CLINICAL CANCER RESEARCH 5 (November 1, 1999): 3755S-3756S.

Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, et al. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin dependent kinase (CDK) 4. CLINICAL CANCER RESEARCH. 1999 Nov 1;5:3755S-3756S.

Kubo, A., et al. “The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin dependent kinase (CDK) 4.” CLINICAL CANCER RESEARCH, vol. 5, AMER ASSOC CANCER RESEARCH, Nov. 1999, pp. 3755S-3756S.

Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, Testa JR, Johnson BE, Kaye FJ, Kelley MJ. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin dependent kinase (CDK) 4. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 1999 Nov 1;5:3755S-3756S.